FiercePharma

FTC Study: In FY 2012, Branded Drug Firms Significantly Increased the Use of Potential Pay-for-Delay Settlements to Keep Generic Competitors off the Market

Record Number of Agreements Cover 31 Different Products, With Combined Annual U.S. Sales of More Than $8.3 Billion In Fiscal Year (FY) 2012, the number of potentially anticompetitive patent dispute ...
searchenginewatch

Branded vs. Non-Branded SEM

Whether a company should bid on their own brand name to fortify their search position is a subject of fierce debate. There are reasonable arguments both for and against the issue. This article is ...
Digi Times

Digitimes Research: Branded tablet shipments hit 109 million in 2012

Global branded tablet shipments enjoyed better than forecast growth, rising 63% sequentially and 100.3% on year, to 43.22 million units in the fourth quarter of 2012, according to Digitimes Research ...
Marketing

Online Branded Communities: Best-Practices, Top-Performing Brands and Sectors

Over the past year, America's top brands have made few improvements in how they use online branded communities to reach their customers, according to a report released today by ComBlu. Among some 219 ...
IPWatchdog

In FY 2012, Branded Drug Firms Increased the Use of Pay-for-Delay Settlements to Keep Generic Competitors off the Market

In Fiscal Year (FY) 2012, the number of potentially anticompetitive patent dispute settlements between branded and generic drug companies increased significantly compared with FY 2011, jumping from 28 ...